Robert Sugerman, MD
Allergy & Immunology · Dallas, TXNPI 1598759862
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,444 of the $9,255 with a category attached, or 69.6%. 36 manufacturers reported payments, led by ADMA Biomanufacturing LLC at 30.5% of the total. Reporting peaked in 2024 at $4,185 and has fallen 63.4% since, to $1,534 in 2025.
Across 262 payments — averaging $35.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADMA Biomanufacturing LLC$3K
- Takeda Pharmaceuticals U.S.A., Inc.$717
- Regeneron Healthcare Solutions, Inc.$628
- Pfizer$607
- Sanofi$474
- CSL Behring$423
- plus $4K from 30 others
Across 2 payments — averaging $6183.75 each. An ownership or investment interest held by the physician or an immediate family member.
- Consortium Of Independent Immunology Clinics, LLC$12K
What the payments were for
- Consulting fees$270%
- Speaking & faculty fees$2,50027%
- Travel & lodging$2503%
- Food & beverage$6,44470%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADMA Biomanufacturing LLC | 4 | $2,822 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $717 |
| Regeneron Healthcare Solutions, Inc. | 19 | $628 |
| Pfizer | 24 | $607 |
| Sanofi | 21 | $474 |
| CSL Behring | 8 | $423 |
| Consortium Of Independent Immunology Clinics, LLC | 1 | $400 |
| AstraZeneca | 19 | $340 |
| Octapharma USA, Inc. | 14 | $333 |
| Grifols USA, LLC | 8 | $310 |
| GSK | 17 | $277 |
| Novartis | 10 | $233 |
| Kaleo, Inc. | 14 | $226 |
| Genentech USA, Inc. | 8 | $187 |
| Pharming Healthcare, Inc. | 6 | $146 |
| Amgen | 6 | $130 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $105 |
| Optinose US, Inc. | 5 | $84 |
| Phadia US Inc. | 6 | $81 |
| Hospira, Inc. | 5 | $80 |
| Covis Pharma GmbH | 4 | $72 |
| Organon | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 4 | $64 |
| Blueprint Medicines Corporation | 3 | $62 |
| Azurity Pharmaceuticals, Inc. | 3 | $61 |
| GC Biopharma USA, Inc. | 2 | $55 |
| LEO Pharma Inc. | 2 | $48 |
| Kedrion Biopharma, Inc. | 2 | $48 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Shire North American Group Inc | 2 | $28 |
| Insmed, Inc. | 1 | $23 |
| Galderma Laboratories, L.p. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $19 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,255 in reported general payments places this provider in the 60th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 35 | $372,598 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $199,267 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,479 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $3,617 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,704 |
| Hydroxyzine Hcl | 20 | $582 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $344 |
| Montelukast Sodium | 28 | $264 |
| Azithromycin | 21 | $160 |
| Azelastine Hcl | 17 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $423 | $372,59835 claims |
| PfizerOctagam | $607 | $199,26713 claims |
| GSKBreo Ellipta | $277 | $5,47911 claims |
| AstraZenecaSymbicort | $340 | $2,70411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Dallas
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lara GrossDallas$171K
- Sonak DaulatDallas$72K
- Joseph WestDallas$39K
- Anil NandaDallas$35K
- Joseph DiazSan Antonio$1.1M
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.